Intile Joanne L, Rassnick Kenneth M, Al-Sarraf Renee, Chretin John D
From the Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina (J.L.I.); Veterinary Medical Center of Central New York, Syracuse, New York (K.M.R.); Animal Emergency and Referral Associates, Fairfield, New Jersey (R.A-S.); and VCA West Los Angeles Animal Hospital, Los Angeles, California (J.D.C).
J Am Anim Hosp Assoc. 2019 Mar/Apr;55(2):101-109. doi: 10.5326/JAAHA-MS-6878. Epub 2019 Jan 17.
Combination chemotherapy can be an effective option for treating resistant lymphoma in dogs. This retrospective study examined the tolerability and efficacy of the combination of 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide (dacarbazine) (DTIC) in a population of dogs with lymphoma resistant to a doxorubicin-containing chemotherapy protocol. Mitoxantrone was administered at 5 mg/m IV over 10 min followed by DTIC at 600 mg/m IV over 5 hr, every 3 wk. All dogs were treated with prophylactic trimethoprim-sulfadiazine and metoclopramide. The frequency of grade 4 neutropenia was 18%, and 5% of dogs were hospitalized from sepsis. Gastrointestinal toxicity was uncommon. The overall response rate was 34% (15 of 44; 95% confidence interval 20-48%) for a median duration of 97 days (range 24-636 days, 95% confidence interval 44-150 days). Fourteen of 15 dogs who received mitoxantrone and DTIC as first rescue responded to treatment. Dogs who achieved complete remission to their initial L-asparaginase, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy protocol were more likely to respond to mitoxantrone and DTIC (23 versus 11%, P = .035). The combination of mitoxantrone and DTIC is a safe treatment option for resistant lymphoma in dogs.
联合化疗可能是治疗犬耐药性淋巴瘤的有效选择。这项回顾性研究检验了5 -（3,3 - 二甲基 - 1 - 三氮烯）- 咪唑 - 4 - 甲酰胺（达卡巴嗪）（DTIC）联合用药在一群对含阿霉素化疗方案耐药的淋巴瘤犬中的耐受性和疗效。米托蒽醌以5mg/m²静脉注射，持续10分钟，随后DTIC以600mg/m²静脉注射，持续5小时，每3周一次。所有犬均接受预防性甲氧苄啶 - 磺胺嘧啶和胃复安治疗。4级中性粒细胞减少的发生率为18%，5%的犬因败血症住院。胃肠道毒性不常见。总体缓解率为34%（44只中的15只；95%置信区间20 - 48%），中位缓解持续时间为97天（范围24 - 636天，95%置信区间44 - 150天）。15只接受米托蒽醌和DTIC作为首次挽救治疗的犬中有14只对治疗有反应。对初始的L - 天冬酰胺酶、环磷酰胺、阿霉素、长春新碱和泼尼松化疗方案达到完全缓解的犬更有可能对米托蒽醌和DTIC有反应（23%对11%，P = 0.035）。米托蒽醌和DTIC联合用药是犬耐药性淋巴瘤的一种安全治疗选择。
